|
[posting]61179708[/posting]Auszug aus dem Earnings Call Transcript Mai 09, 2019 In addition, the Committee for Medicinal Products for Human Use of the European Medicines Agency has provided advice on the European Union Vyleesi development program, indicating that only a single Phase III study in the European Union is needed to support a licensing application. And in terms of the work that's going on outside the United States for Vyleesi, how should we be thinking about additional partnerships in territories that are not currently licensed? Is that something that you think would be more of a near-term event or probably something that will take a bit more time? We're in advancing discussions right now with multiple parties. Nothing is going to happen before the FDA's PDUFA date, but we're -- we've been socializing now for a few quarters because it takes time to get people acclimated to where you've been and where you're going. So we're -- I'm going to go a little aggressive with this position, but we expect that we will have multiple rest of the world in the non-licensed territories executed before the end of calendar 2019. Ferner heißt es So we're really targeting the fourth quarter, so the fall going into the winter. But we do believe we will have multiple regions licensed by the end of calendar 2019. Ich kann mir vorstellen, falls Palatin wirklich einen Lizenzpartner für Europa bis Ende 2019 finden sollte, dass die Aktien dann etwas steigen werden. Ich kann mir allerdings nicht vorstellen, dass die Aktie wieder einen Preis von 1,80 euro erreichen werden. Wie ist eure Meinung dazu? |
|
| aus der Diskussion: | Palatin Technology / voraussichtliches Marktpotential von 1,3 Mrd $ bis 2020 allein in USA |
| Autor (Datum des Eintrages): | Aktapot (05.08.19 20:21:31) |
| Beitrag: | 4,509 von 5,764 (ID:61179813) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |